Immune dysregulation in immune thrombocytopenia

Seminars in Hematology

Volumn 50, Issue SUPPL.1, 2013, Pages

  Yazdanbakhsh, Karina ^a   Zhong, Hui ^a   Bao, Weili ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; DEXAMETHASONE; INTERLEUKIN 10; INTERLEUKIN 12; RITUXIMAB; THROMBOPOIETIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; DRUG MEGADOSE; EFFECTOR CELL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DYSREGULATION; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; TH1 CELL; TH17 CELL; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS;

HUMANS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; THROMBOCYTOPENIA;

EID: 84877652698     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.03.011     Document Type: Article

References (47)

1. Gernsheimer T. Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis. Oncologist 2009, 14:12-21.
2. Roark J.H., Bussel J.B., Cines D.B., Siegel D.L. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood 2002, 100:1388-1398.
3. Semple J.W., Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 1991, 78:2619-2625.
4. Semple J.W., Milev Y., Cosgrave D., et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996, 87:4245-4254.
5. Ogawara H., Handa H., Morita K., et al. High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2003, 71:283-288.
6. Kuwana M., Kaburaki J., Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest 1998, 102:1393-1402.
7. Kuwana M., Kaburaki J., Kitasato H., et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood 2001, 98:130-139.
8. Rocha A.M., Souza C., Rocha G.A., et al. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica 2011, 96:1560-1564.
9. Zhu X., Ma D., Zhang J., et al. Elevated interleukin-21 correlated to Th17 and Th1 cells in patients with immune thrombocytopenia. J Clin Immunol 2010, 30:253-259.
10. Zhang J., Ma D., Zhu X., et al. Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica 2009, 94:1326-1329.
11. Wang J.D., Chang T.K., Lin H.K., et al. Reduced expression of transforming growth factor-beta1 and correlated elevation of interleukin-17 and interferon-gamma in pediatric patients with chronic primary immune thrombocytopenia (ITP). Pediatr Blood Cancer 2011, 57:636-640.
12. Sollazzo D., Trabanelli S., Curti A., et al. Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia. Haematologica 2011, 96:632-634.
13. Cao J., Chen C., Li L., et al. Effects of high-dose dexamethasone on regulating interleukin-22 production and correcting Th1 and Th22 polarization in immune thrombocytopenia. J Clin Immunol 2012, 32:523-529.
14. Olsson B., Andersson P.O., Jernas M., et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003, 9:1123-1124.
15. Zhang F., Chu X., Wang L., et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2006, 76:427-431.
16. Li S., Wang L., Zhao C., et al. CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br J Haematol 2007, 139:605-611.
17. Sakakura M., Wada H., Tawara I., et al. Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 2007, 120:187-193.
18. Liu B., Zhao H., Poon M.C., et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007, 78:139-143.
19. Ling Y., Cao X., Yu Z., Ruan C. Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol 2007, 79:310-316.
20. Stasi R., Cooper N., Del Poeta G., et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008, 112:1147-1150.
21. Yu J., Heck S., Patel V., et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008, 112:1325-1328.
22. Audia S., Samson M., Guy J., et al. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood 2011, 118:4394-4400.
23. Li X., Zhong H., Bao W., et al. Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood 2012, 120:3318-3325.
24. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490-500.
25. Buckner J.H. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010, 10:849-859.
26. Zhang X.L., Peng J., Sun J.Z., et al. De novo induction of platelet-specific CD4(+)CD25(+) regulatory T cells from CD4(+)CD25(-) cells in patients with idiopathic thrombocytopenic purpura. Blood 2009, 113:2568-2577.
27. Fillatreau S., Sweenie C.H., McGeachy M.J., Gray D., Anderton S.M. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002, 3:944-950.
28. Moulin V., Andris F., Thielemans K., et al. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med 2000, 192:475-482.
29. Blair P.A., Norena L.Y., Flores-Borja F., et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010, 32:129-140.
30. Carter N.A., Vasconcellos R., Rosser E.C., et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol 2011, 186:5569-5579.
31. Amu S., Saunders S.P., Kronenberg M., et al. Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J Allergy Clin Immunol 2010, 125:1114-1124.
32. Auffray C., Sieweke M.H., Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Ann Rev Immunol 2009, 27:669-692.
33. Serbina N.V., Jia T., Hohl T.M., Pamer E.G. Monocyte-mediated defense against microbial pathogens. Ann Rev Immunol 2008, 26:421-452.
34. Evans H.G., Gullick N.J., Kelly S., et al. In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses. Proc Natl Acad Sci U S A 2009, 106:6232-6237.
35. Movahedi K., Guilliams M., Van den Bossche J., et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111:4233-4244.
36. Ziegler-Heitbrock L., Ancuta P., Crowe S., et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 116:e74-e80.
37. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 2007, 81:584-592.
38. Mobley J.L., Leininger M., Madore S., Baginski T.J., Renkiewicz R. Genetic evidence of a functional monocyte dichotomy. Inflammation 2007, 30:189-197.
39. Zhong H, Bao W, Li X, et al. CD16+ monocytes control T cell subset development in immune thrombocytopenia. Blood. 2012;120:3326-35.
40. Bussel J.B., Kuter D.J. New thrombopoietic agents: introduction. Semin Hematol 2010, 47:211.
41. Bao W., Bussel J.B., Heck S., et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010, 116:4639-4645.
42. Solanilla A., Pasquet J.M., Viallard J.F., et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 2005, 105:215-218.
43. May A.E., Kalsch T., Massberg S., et al. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 2002, 106:2111-2117.
44. Sanz I., Lee F.E. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6:326-337.
45. Zhong H, Bao W, Li X, et al. CD16+ monocytes control T-cell subset development in immune thrombocytopenia. Blood. 2012;120:3326-35.
46. Perreault S., Burzynski J. Romiplostim: a novel thrombopoiesis-stimulating agent. Am J Health Syst Pharm 2009, 66:817-824.
47. Olnes M.J., Scheinberg P., Calvo K.R., et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012, 367:11-19.